It’s a New Era: Culture-Independent Tests for Rapid Detection of Sepsis-Causing Pathogens that Lead to Positive Healthcare Outcomes

Tuesday, September 28, 3:30 - 4:30 p.m.
Exhibit Hall, Theater 1
Supported by T2 Biosystems


Culture-independent tests have shifted the paradigm in species identification for blood stream infections. Current diagnostic tests for blood stream infections have limited sensitivity and extended time to identification of sepsis causative pathogens. T2 Biosystems Panels detect sepsis-causing pathogens direct from whole blood. Faster identification of causative pathogens with T2 Biosystems Panels leads to positive clinical and economic outcomes in sepsis patients, including reduced length of hospital stay, improved savings in hospital costs, and improved antimicrobial/antifungal stewardship.


After attending this session, participants will be able to:

  • Compare culture-independent testing versus current diagnostic testing and the implications on healthcare outcomes, antimicrobial, and antifungal stewardship.
  • Review the successful experience with T2 Biosystems Panels in the detection of sepsis-causing pathogens.
  • Describe how “Choosing Wisely” can provide an effective framework for driving practice changes.


Thomas Walsh, MD, PhD
Director of the Transplantation-Oncology Infectious Diseases Program in the Division of Infectious Diseases of the Department of Medicine
New York-Presbyterian Hospital/Weill Cornell Medical Center
New York, NY

Denise Geiger, PhD, DLM (ASCP)
Clinical Transformation Liaison
Mather Hospital
New York, NY

Aparna Ahuja, MD
Chief Medical Officer
T2 Biosystems
Lexington, MA